摘要
目的:初步评估保罗青光眼植入物在青光眼治疗中的有效性和安全性。方法:回顾性分析2022-03/2023-01接受保罗青光眼植入物治疗的青光眼患者10例10眼的临床资料。至少随访12 mo,观察手术前后视力、眼压和抗青光眼用药数量等指标的变化。结果:纳入患者末次随访时视力较术前无明显变化;术前眼压19-60(中位数28)mmHg,末次随访时眼压为10-18(中位数14)mmHg。术前所有患者均需使用2-4种抗青光眼药物,末次随访时仅1例患者需使用。4例患者末次随访时角膜内皮细胞密度较术前明显下降,未发生角膜相关并发症。截至末次随访,10例患者均获得手术成功。结论:保罗青光眼植入物具有显著的降眼压疗效,角膜内皮细胞损害可能是其存在的隐患。
AIM:To preliminarily assess the efficacy and safety of PAUL glaucoma implant in glaucoma management.METHODS:Clinical data of 10 glaucoma patients(10 eyes)who treated with Paul’s glaucoma implant from March 2022 to January 2023 were retrospectively analyzed.A follow-up of 12 mo was performed to observe changes in visual acuity,intraocular pressure,and number of anti-glaucoma medications before and after surgery.RESULTS:Included patients had no significant change in visual acuity from preoperative to last follow-up;preoperative intraocular pressure was 19-60(median 28)mmHg,and it was 10-18(median 14)mmHg at last follow-up.All patients required two to four antiglaucoma medications preoperatively,and only 1 case needed medications at final follow-up.Four patients had a significant decrease in corneal endothelial cell density compared with the preoperative period,and no corneal-related complications occurred.At final follow-up,all 10 patients met surgical success criteria.CONCLUSION:PAUL glaucoma implant has significant IOP lowering efficacy and that corneal endothelial cell damage may be a pitfall of its presence.
作者
胡甜
陈志祺
张虹
Hu Tian;Chen Zhiqi;Zhang Hong(Department of Ophthalmology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei Province,China;Jiangxi Provincial People’s Hospital,the First Affiliated Hospital of Nanchang Medical College,Nanchang 330000,Jiangxi Province,China)
出处
《国际眼科杂志》
CAS
2024年第7期1168-1172,共5页
International Eye Science
基金
国家自然科学基金资助项目(No.82070965)。
关键词
保罗青光眼植入物
青光眼
眼压
手术疗效
安全性
PAUL glaucoma implant
glaucoma
intraocular pressure
surgical outcomes
safety
